TriSalus Life Sciences (TLSI) Earnings Date & Reports

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TLSI is expected to report earnings to fall 63.50% to -14 cents per share on August 19

TriSalus Life Sciences TLSI Stock Earnings Reports

Q2'26

Est.

$-0.15

Q4'24

Beat

by $0.08

The last earnings report on April 15 showed earnings per share of -40 cents, beating the estimate of -47 cents. With 85.50K shares outstanding, the current market capitalization sits at 257.95M.

View a ticker or compare two or three

Compare

TLSI

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for TLSI